Johnson Johnson AbbVie: Paths to Pharma Dominance
Johnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Quick take on safety: bonds vs cash in retirement, highlighting scenarios where each preserves capital and meets withdrawal needs.
24,731 articlesJohnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Lam Research sits at the core of AI infrastructure tooling. This article explores whether the company could research ...
NVIDIA leads the AI hardware wave while Palantir gains momentum on enterprise software. Investors debate which stock ...
Optimum (OPTU) is reshaping its strategy in 2026. This original analysis dives into the Q1 results, margins, and capi...
Two tech giants reported divergent Q1 results as they sprint into AI. Meta dominates ads but burns cash on Reality La...
A looming repair bill for U.S. defense infrastructure could lift demand for certain contractors. This guide explains ...
As the BNPL market matures, Affirm and Klarna face distinct paths to growth. This guide dives into business models, f...
Intuitive Machines announced an $800 million acquisition that pivots the company from lunar landers to a full space p...
Ford is plotting a bold move with ford's next generation electric—a scalable, low-cost EV platform designed to suppor...
Behind every AI breakthrough lies a power backstop. This article explains how Vertiv quietly powering every AI data c...
Wolverine Worldwide's Q1 2026 earnings call offers a clear view of the company's momentum, margins, and strategic bet...
A consortium led by Barry Diller has proposed a $12.4 billion bid to take MGM Resorts private, a move that could resh...